Second-generation antipsychotics in the treatment of major depressive disorder: current evidence

References

• Kessler RC, Berglund P, Demler O et al.; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23), 3095–3105 (2003).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Warden D, Wisniewski SR et al. STAR*D: revising conventional wisdom. CNS Drugs 23(8), 627–647 (2009).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur. Neuropsychopharmacol. 19(1), 34–40 (2009).
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Husain MM, Trivedi MH et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol. Med. 40(1), 41–50 (2010).
   PubMed Web of Science ®Google Scholar
• Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol. Med. 25(6), 1171–1180 (1995).
   PubMed Web of Science ®Google Scholar
• Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J. Clin. Psychiatry 64(Suppl. 13), 18–25 (2003).
   PubMedGoogle Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am. J. Psychiatry 157(Suppl. 4), 1–45 (2000).
   Web of Science ®Google Scholar
• Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ; World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: acute and continuation treatment of major depressive disorder. World J. Biol. Psychiatry 3(1), 5–43 (2002).
   PubMedGoogle Scholar
• Anderson IM, Ferrier IN, Baldwin RC et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J. Psychopharmacol. (Oxford) 22(4), 343–396 (2008).
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Lam RW, Cohen NL, Ravindran AV; CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can. J. Psychiatry 46(Suppl. 1), S38–S58 (2001).
   PubMedGoogle Scholar
• Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 166(9), 980–991 (2009).
   PubMed Web of Science ®Google Scholar
• Robertson MM, Trimble MR. Neuroleptics as antidepressants. Neuropharmacology 20(12B), 1335–1336 (1981).
   PubMedGoogle Scholar
• Sagud M, Mihaljevic-Peleš A, Begic D et al. Antipsychotics as antidepressants: what is the mechanism? Psychiatr. Danub. 23(3), 302–307 (2011).
   PubMed Web of Science ®Google Scholar
• Yoshino T, Nisijima K, Katoh S, Yui K, Nakamura M. Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochem. Int. 40(4), 355–360 (2002).
   PubMed Web of Science ®Google Scholar
• Gobert A, Rivet JM, Cistarelli JM, Millan MJ. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J. Neurochem. 68(3), 1326–1329 (1997).
   PubMed Web of Science ®Google Scholar
• DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther. 26(5), 649–666 (2004).
   PubMed Web of Science ®Google Scholar
• Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 22(5), 367–388 (2008).
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302(1), 381–389 (2002).
   PubMed Web of Science ®Google Scholar
• De Vry J, Schreiber R, Melon C, Dalmus M, Jentzsch KR. 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. Eur. Neuropsychopharmacol. 14(6), 487–495 (2004).
   PubMed Web of Science ®Google Scholar
• Dremencov E, Newman ME, Kinor N et al. Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 48(1), 34–42 (2005).
   PubMed Web of Science ®Google Scholar
• Pira L, Mongeau R, Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur. J. Pharmacol. 504(1–2), 61–64 (2004).
   PubMed Web of Science ®Google Scholar
• Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur. J. Pharmacol. 368(2–3), 277–283 (1999).
   PubMed Web of Science ®Google Scholar
• Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel anti-psychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. 425(3), 197–201 (2001).
   PubMed Web of Science ®Google Scholar
• Wesolowska A. Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. Pharmacol. Rep. 62(4), 564–577 (2010).
   PubMed Web of Science ®Google Scholar
• Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl.) 206(3), 345–354 (2009).
   PubMed Web of Science ®Google Scholar
• Tascedda F, Lovati E, Blom JM et al. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology 21(2), 211–217 (1999).
   PubMed Web of Science ®Google Scholar
• de Borja Gonçalves Guerra A, Castel S, Benedito-Silva AA, Calil HM. Neuroendocrine effects of quetiapine in healthy volunteers. Int. J. Neuropsychopharmacol. 8(1), 49–57 (2005).
   PubMed Web of Science ®Google Scholar
• Myint AM, Kim YK, Verkerk R, Scharpé S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 98(1–2), 143–151 (2007).
   PubMed Web of Science ®Google Scholar
• McEwen BS, Olié JP. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol. Psychiatry 10(6), 525–537 (2005).
   PubMed Web of Science ®Google Scholar
• Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 1043(1–2), 32–41 (2005).
   PubMed Web of Science ®Google Scholar
• Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J. Clin. Psychiatry 66(Suppl. 8), 30–40 (2005).
   PubMed Web of Science ®Google Scholar
• Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J. Affect. Disord. 86(1), 99–104 (2005).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Kinrys G et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J. Clin. Psychiatry 66(10), 1326–1330 (2005).
   PubMed Web of Science ®Google Scholar
• Pae CU, Patkar AA, Jun TY, Lee C, Masand PS, Paik IH. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress. Anxiety 24(7), 522–526 (2007).
   PubMed Web of Science ®Google Scholar
• Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J. Clin. Psychiatry 66(10), 1216–1220 (2005).
   PubMed Web of Science ®Google Scholar
• Patkar AA, Peindl K, Mago R, Mannelli P, Masand PS. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim. Care Companion J. Clin. Psychiatry 8(2), 82–87 (2006).
   PubMedGoogle Scholar
• Rutherford B, Sneed J, Miyazaki M et al. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. Int. J. Geriatr. Psychiatry 22(10), 986–991 (2007).
   PubMed Web of Science ®Google Scholar
• Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann. Clin. Psychiatry 16(4), 189–194 (2004).
   PubMedGoogle Scholar
• Worthington JJ 3rd, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int. Clin. Psychopharmacol. 20(1), 9–11 (2005).
   PubMed Web of Science ®Google Scholar
• Schüle C, Baghai TC, Eser D et al. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World J. Biol. Psychiatry 8(2), 112–122 (2007).
   PubMed Web of Science ®Google Scholar
• Hellerstein DJ, Batchelder S, Hyler S et al. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(3), 744–750 (2008).
   PubMed Web of Science ®Google Scholar
• Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68(6), 843–853 (2007).
   PubMed Web of Science ®Google Scholar
• Marcus RN, McQuade RD, Carson WH et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 28(2), 156–165 (2008).
   PubMed Web of Science ®Google Scholar
• Berman RM, Fava M, Thase ME et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 14(4), 197–206 (2009).
   PubMed Web of Science ®Google Scholar
• Fava M, Mischoulon D, Iosifescu D et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother. Psychosom. 81(2), 87–97 (2012).
   PubMed Web of Science ®Google Scholar
• Mischoulon D, Witte J, Levy M et al. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J. Clin. Psychiatry 73(3), 353–357 (2012).
   PubMed Web of Science ®Google Scholar
• Thase ME, Trivedi MH, Nelson JC et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim. Care Companion J. Clin. Psychiatry 10(6), 440–447 (2008).
   PubMedGoogle Scholar
• Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E. Remission, response without remission, and non-response in major depressive disorder: impact on functioning. Int. Clin. Psychopharmacol. 24(3), 133–138 (2009).
   PubMed Web of Science ®Google Scholar
• Nelson JC, Thase ME, Bellocchio EE et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int. Clin. Psychopharmacol. 27(3), 125–133 (2012).
   PubMed Web of Science ®Google Scholar
• Steffens DC, Nelson JC, Eudicone JM et al. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. Int. J. Geriatr. Psychiatry 26(6), 564–572 (2011).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Thase ME, Fava M et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J. Clin. Psychiatry 69(12), 1928–1936 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson JC, Mankoski R, Baker RA et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J. Affect. Disord. 120(1–3), 133–140 (2010).
   PubMed Web of Science ®Google Scholar
• Reimherr FW, Martin ML, Eudicone JM et al. A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole. J. Clin. Psychopharmacol. 30(3), 300–305 (2010).
   Google Scholar
• Berman RM, Thase ME, Trivedi MH et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr. Dis. Treat. 7, 303–312 (2011).
   PubMed Web of Science ®Google Scholar
• Fava M, Wisniewski SR, Thase ME et al. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J. Clin. Psychopharmacol. 29(4), 362–367 (2009).
   PubMed Web of Science ®Google Scholar
• Fava M, Dording CM, Baker RA et al. Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. Prim. Care Companion CNS Disord. 13(1), pii: PCC.10m00994 (2011).
   Google Scholar
• Nelson JC, Thase ME, Trivedi MH et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163). Prim. Care Companion J. Clin. Psychiatry 11(6), 344–352 (2009).
   PubMedGoogle Scholar
• Anderson IM, Sarsfield A, Haddad PM. Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study. J. Affect Disord. 117(1–2), 116–119 (2009).
   PubMed Web of Science ®Google Scholar
• Soares CN, Frey BN, Haber E, Steiner M. A pilot, 8-week, placebo lead-in trial of quetiapine extended release for depression in midlife women: impact on mood and menopause-related symptoms. J. Clin. Psychopharmacol. 30(5), 612–615 (2010).
   PubMed Web of Science ®Google Scholar
• Katila H, Mezhebovsky I, Mulroy A et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am. J. Geriatr. Psychiatry (2012) (Epub ahead of print).
   Google Scholar
• Bortnick B, El-Khalili N, Banov M et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J. Affect. Disord. 128(1–2), 83–94 (2011).
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress. Anxiety 27(10), 964–976 (2010).
   PubMed Web of Science ®Google Scholar
• Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H; Moonstone Study Group. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 14(6), 299–313 (2009).
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J. Clin. Psychiatry 70(4), 526–539 (2009).
   PubMed Web of Science ®Google Scholar
• Earley WMA, Wang G. Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). Presented at: The 8th International Forum on Mood and Anxiety Disorder. Vienna, Austria, 12–14 November 2008.
   Google Scholar
• El-Khalili N, Joyce M, Atkinson S et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. 13(7), 917–932 (2010).
   PubMed Web of Science ®Google Scholar
• Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J. Clin. Psychiatry 70(4), 540–549 (2009).
   PubMed Web of Science ®Google Scholar
• Garakani A, Martinez JM, Marcus S et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int. Clin. Psychopharmacol. 23(5), 269–275 (2008).
   PubMed Web of Science ®Google Scholar
• Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry 8, 73 (2008).
   PubMed Web of Science ®Google Scholar
• McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress. Anxiety 24(7), 487–494 (2007).
   PubMed Web of Science ®Google Scholar
• Wijkstra J, Burger H, van den Broek WW et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr. Scand. 121(3), 190–200 (2010).
   PubMed Web of Science ®Google Scholar
• Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry 12, 160 (2012).
   Google Scholar
• Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress. Anxiety 29(7), 574–586 (2012).
   PubMed Web of Science ®Google Scholar
• Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int. Clin. Psychopharmacol. 27(1), 27–39 (2012).
   Google Scholar
• Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 158(1), 131–134 (2001).
   PubMed Web of Science ®Google Scholar
• Shelton RC, Williamson DJ, Corya SA et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry 66(10), 1289–1297 (2005).
   PubMed Web of Science ®Google Scholar
• Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress. Anxiety 23(6), 364–372 (2006).
   PubMed Web of Science ®Google Scholar
• Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J. Clin. Psychiatry 68(2), 224–236 (2007).
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Williamson DJ, Tohen MF et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J. Clin. Psychopharmacol. 24(4), 365–373 (2004).
   PubMed Web of Science ®Google Scholar
• Meyers BS, Flint AJ, Rothschild AJ et al.; STOP-PD Group. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch. Gen. Psychiatry 66(8), 838–847 (2009).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Thase ME, Osuntokun O et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J. Clin. Psychiatry 70(3), 387–396 (2009).
   PubMed Web of Science ®Google Scholar
• Tohen M, Case M, Trivedi MH, Thase ME, Burke SJ, Durell TM. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J. Clin. Psychiatry 71(4), 451–462 (2010).
   PubMed Web of Science ®Google Scholar
• Corya SA, Andersen SW, Detke HC et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J. Clin. Psychiatry 64(11), 1349–1356 (2003).
   PubMed Web of Science ®Google Scholar
• Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J. Clin. Psychiatry 60(4), 256–259 (1999).
   PubMed Web of Science ®Google Scholar
• Viner MW, Chen Y, Bakshi I, Kamper P. Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J. Clin. Psychopharmacol. 23(1), 104–106 (2003).
   PubMed Web of Science ®Google Scholar
• Mahmoud RA, Pandina GJ, Turkoz I et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann. Intern. Med. 147(9), 593–602 (2007).
   PubMed Web of Science ®Google Scholar
• Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J. Clin. Psychiatry 69(8), 1228–1336 (2008).
   PubMed Web of Science ®Google Scholar
• Keitner GI, Garlow SJ, Ryan CE et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J. Psychiatr. Res. 43(3), 205–214 (2009).
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Gharabawi GM, Canuso CM et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31(11), 2505–2513 (2006).
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Canuso CM, Gharabawi GM et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am. J. Geriatr. Psychiatry 16(1), 21–30 (2008).
   PubMed Web of Science ®Google Scholar
• Fang Y, Yuan C, Xu Y et al.; OPERATION Study Team. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J. Clin. Psychopharmacol. 31(5), 638–642 (2011).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Vitolo OV, Ishak WW et al. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J. Clin. Psychiatry 73(12), 1541–1547 (2012).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Nierenberg AA et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J. Clin. Psychiatry 65(2), 217–221 (2004).
   PubMed Web of Science ®Google Scholar
• Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J. Clin. Psychiatry 68(7), 1071–1077 (2007).
   PubMed Web of Science ®Google Scholar
• Rocca P, Marchiaro L, Rasetti R, Rivoira E, Bogetto F. A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. Psychiatry Res. 112(2), 145–152 (2002).
   PubMed Web of Science ®Google Scholar
• Rocca P, Fonzo V, Ravizza L et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J. Affect. Disord. 70(3), 313–317 (2002).
   PubMed Web of Science ®Google Scholar
• Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia. Eur. Neuropsychopharmacol. 16(4), 281–287 (2006).
   PubMed Web of Science ®Google Scholar
• Cassano GB, Jori MC; AMIMAJOR Group. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int. Clin. Psychopharmacol. 17(1), 27–32 (2002).
   PubMed Web of Science ®Google Scholar
• Ravizza L. Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators. J. Psychopharmacol. (Oxford) 13(3), 248–254 (1999).
   PubMed Web of Science ®Google Scholar
• Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 39(1), 25–32 (1999).
   PubMed Web of Science ®Google Scholar
• Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J. Affect. Disord. 48(1), 47–56 (1998).
   PubMed Web of Science ®Google Scholar
• Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J. Affect. Disord. 43(2), 95–103 (1997).
   PubMed Web of Science ®Google Scholar
• León CA, Vigoya J, Conde S, Campo G, Castrillón E, León A. [Comparison of the effect of amisulpride and viloxazine in the treatment of dysthymia]. Acta Psiquiatr. Psicol. Am. Lat. 40(1), 41–49 (1994).
   Google Scholar
• Amore M, Jori MC; AMISERT Investigators. Faster response on amisulpride 50 mg versus sertraline 50–100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int. Clin. Psychopharmacol. 16(6), 317–324 (2001).
   PubMed Web of Science ®Google Scholar
• Yang FW, Liang CS. Paliperidone augmentation for treatment-resistant depression: a case report. J. Clin. Psychopharmacol. 31(2), 245–246 (2011).
   Google Scholar
• Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin. Pharmacother. 13(13), 1911–1922 (2012).
   PubMed Web of Science ®Google Scholar
• Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can. J. Psychiatry 45(5), 476–481 (2000).
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Dusetzina SB, Ellis AR et al. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J. Clin. Psychopharmacol. 32(1), 114–119 (2012).
   PubMed Web of Science ®Google Scholar
• Wisniewski SR, Fava M, Trivedi MH et al. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am. J. Psychiatry 164(5), 753–760 (2007).
   PubMed Web of Science ®Google Scholar
• Warden D, Rush AJ, Wisniewski SR et al. What predicts attrition in second step medication treatments for depression?: a STAR*D Report. Int. J. Neuropsychopharmacol. 12(4), 459–473 (2009).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Green C et al. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann. Clin. Psychiatry 17(3), 161–165 (2005).
   PubMedGoogle Scholar
• Rush AJ, Trivedi MH, Stewart JW et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 168(7), 689–701 (2011).
   PubMed Web of Science ®Google Scholar
• Pae CU, Han C, Jun TY. Do we need more than one antidepressant for patients with major depressive disorder? Expert Rev. Neurother. 11(11), 1561–1564 (2011).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163(11), 1905–1917 (2006).
   PubMed Web of Science ®Google Scholar
• Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can. J. Psychiatry 52(1), 46–54 (2007).
   PubMed Web of Science ®Google Scholar
• Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr. Clin. North Am. 19(2), 179–200 (1996).
   PubMed Web of Science ®Google Scholar
• Lin CH, Lin SH, Jang FL. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. J. Clin. Psychopharmacol. 31(5), 563–568 (2011).
   Google Scholar
• Rush AJ, Wisniewski SR, Zisook S et al. Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. Psychol. Med. 42(6), 1131–1149 (2012).
   Google Scholar
• Nierenberg AA, Trivedi MH, Gaynes BN et al. Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder. Aus. New Zealand J. Psychiatry 43(10), 956–967 (2009).
   Web of Science ®Google Scholar
• Chen SJ, Hsiao YL, Shen TW, Chen ST. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial. J. Clin. Psychopharmacol. 32(1), 56–60 (2012).
   Google Scholar
• Jang SH, Park YN, Jae YM et al. The symptom frequency characteristics of the Hamilton Depression Rating Scale and possible symptom clusters of depressive disorders in Korea: the CRESCEND Study. Psychiatry Investig. 8(4), 312–319 (2011).
   Google Scholar
• Hwang SH, Rhee MK, Kang RH et al. Development and validation of a screening scale for depression in Korea: the Lee and Rhee Depression Scale. Psychiatry Investig. 9(1), 36–44 (2012).
   Google Scholar
• Park YM, Lee SH, Park EJ. Usefulness of LDAEP to predict tolerability to SSRIs in major depressive disorder: a case report. Psychiatry Investig. 9(1), 80–82 (2012).
   Google Scholar
• Lee MS, Ahn YM, Chung S, Walton R, Raskin J, Kim MS. The effect of initial duloxetine dosing strategy on nausea in Korean patients with major depressive disorder. Psychiatry Investig. 9(4), 391–399 (2012).
   Web of Science ®Google Scholar
• Son SH, Jo H, Rim HD et al. A comparative study on alexithymia in depressive, somatoform, anxiety, and psychotic disorders among Koreans. Psychiatry Investig. 9(4), 325–331 (2012).
   PubMed Web of Science ®Google Scholar
• Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 25(2), 109–127 (2011).
   PubMed Web of Science ®Google Scholar
• Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J. Clin. Psychopharmacol. 28(2), 203–209 (2008).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova A, Mori N, Keck PE Jr. Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert Opin. Investig. Drugs 19(12), 1527–1544 (2010).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Park KY, Law CW et al. The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs 24(9), 741–753 (2010).
   PubMed Web of Science ®Google Scholar
• Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr. Opin. Psychiatry 24(1), 10–17 (2011).
   PubMed Web of Science ®Google Scholar
• Lam RW, Kennedy SH, Grigoriadis S et al.; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J. Affect. Disord. 117(Suppl. 1), S26–S43 (2009).
   PubMed Web of Science ®Google Scholar
• Härter M, Klesse C, Bermejo I, Schneider F, Berger M. Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. Dtsch. Arztebl. Int. 107(40), 700–708 (2010).
   PubMed Web of Science ®Google Scholar
• Pae CU, Sohi MS, Seo HJ et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(7), 1165–1173 (2010).
   PubMed Web of Science ®Google Scholar
• Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr. Dis. Treat. 4(5), 937–948 (2008).
   PubMedGoogle Scholar
• Möller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? Eur. Arch. Psychiatry Clin. Neurosci. 255(3), 190–201 (2005).
   PubMed Web of Science ®Google Scholar
• Wang SM, Han C, Lee SJ, Patkar AA, Pae CU, Fleischhacker WW. Paliperidone: a review of clinical trial data and clinical implications. Clin. Drug Investig. 32(8), 497–512 (2012).
   PubMed Web of Science ®Google Scholar
• Yatham LN. Mood stabilization and the role of antipsychotics. Int. Clin. Psychopharmacol. 17(Suppl. 3), S21–S27 (2002).
   Google Scholar